Binks Well being Co., Ltd.
BOSTON, Feb. 12, 2024 (Globe Newswire) — binx well being, a healthcare expertise and diagnostics firm centered on increasing point-of-care sexually transmitted an infection testing, has partnered with Cardinal Introduced a nationwide distribution settlement with Well being. Enhance well timed prognosis of chlamydia (CT) and gonorrhea (NG) with the CLIA-exempt and FDA-cleared binx io®.
binx io modifications the paradigm of testing and therapy by delivering outcomes corresponding to central laboratories inside the timeframe of a typical clinic go to. The collaboration with Cardinal Well being will allow binx well being to additional improve its entry to acute scientific care settings via its intensive distribution community within the market. This improved entry will permit sufferers to obtain the advantages of her binx io CT/NG assay of their single go to at clinics, main care places of work, emergency departments, and hospital-affiliated pressing cares throughout the nation. .
“We’re very enthusiastic about this partnership with Cardinal Well being as we increase our business footprint, serving 90% of U.S. hospitals, 29,000 pharmacies, and 10,000 specialty doctor places of work and clinics. ” , whose attain and model are business leaders. We’re proud to have earned the belief in binx and binx io,” mentioned Jeffrey Luber, chief government officer of binx well being.
binx io is the one CLIA-exempt and FDA-cleared molecular point-of-care (POC) platform to detect CT and NG in each female and male affected person samples, delivering central testing efficiency in roughly half-hour To do. Knowledge introduced on the STI & HIV 2023 World Congress in Chicago reveals that the POC binx io turnaround time is statistically the identical because the turnaround time it takes to course of a CT/NG pattern for sending to a central laboratory. We’ve confirmed that. The CT/NG outcomes from binx io had been accessible days earlier than the take a look at outcomes had been accessible from her CT/NG take a look at on the central laboratory .
The central laboratory at present processes 35 million CT/NG assessments yearly. , Most sufferers depart the clinic earlier than they get their outcomes. On this conventional therapy mannequin, as soon as a affected person leaves the clinic and later assessments optimistic for chlamydia or gonorrhea, they could not have the ability to return for therapy, doubtlessly resulting in additional unfold of an infection and issues.
By way of this distribution collaboration, the binx well being and Cardinal Well being groups will work collectively to enhance entry to therapy for CT/NG. For extra details about binx io, please go to: mybinxhealth.com/binx-io Or, contact your Cardinal Well being consultant.
About Binx's well being
binx well being is a healthcare expertise and diagnostics firm centered on innovating options that enhance routine testing and comfort, delivering well timed outcomes to enhance affected person care. binx io point-of-care molecular platform is the first-ever FDA-cleared, CLIA-exempt point-of-care system to offer a central laboratory for the detection of chlamydia and gonorrhea in each males (urine) and ladies (vaginal swabs) is. Efficiency outcomes can be found in roughly half-hour. The binx io platform is versatile, straightforward to make use of, and allows speedy testing and therapy in a single affected person go to.
For extra info, please go to www.mybinxhealth.com.
About Cardinal Well being
Cardinal Well being serves roughly 90% of U.S. hospitals, 20,000 specialty doctor practices and clinics, 6,300 laboratories, and allows 40,000 drug deliveries every day. The group helps its prospects obtain operational effectivity via cost-effective, high-quality scientific merchandise and an aggressive deal with provide chain resilience and reliability. With greater than 70 years of expertise as a number one scientific testing distributor, Cardinal Well being is crucial to your care. Details about Cardinal Well being will be discovered at cardinalhealth.com.
 Lowe KL, Widdis LE et al. Palms-on time and time to outcomes for point-of-care chlamydia and gonorrhea assessments in comparison with laboratory-based assessments. Poster introduced on the STI & HIV 2023 World Congress. July 2023
 Huang W, Gaydos CA et al. (2012). Evaluating the effectiveness of speedy point-of-care assessments for detection of Chlamydia trachomatis in girls in scientific apply. Sextransm an infection. 2013 Mar;89(2):108-14. doi:10.1136/sextrans-2011-050355. Epub 2012 9 14. PMID: 22984085; PMCID: PMC3671871. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3671871/
Stephanie Rideout, Binx Well being
Advertising and marketing communication